FDA Advisory committee recommends against expanded use of Fentora

An FDA Advisory Committee has recommended against the expanded use of Fentora for the management of breakthrough pain in opioid-tolerant patients with chronic pain conditions.

Elixir publish data validating ghrelin as a key metabolic modulator

Elixir have publish data in the journal ‘Regulatory Peptides’ validating ghrelin as a key metabolic modulator. Elixir are developing ghrelin antagonists

GlaxoSmithKline submit NDA for casopitant in chemotherapy-induced nausea and vomiting

GlaxoSmithKline have filed a NDA for its NK-1 receptor antagonist casopitant (Rezonic, Zunrisa) for the treatment of chemotherapy-induced nausea and vomiting. Phase III results show that 86% of patients treated with casopitant demonstrated complete response rates

Phase III data on Resolor (prucalopride) published in NEJM

Phase III data that detail the efficacy an safety of Resolor (prucalopride) in chronic constipation have been  published in The New England Journal of Medicine (NEJM).

Movetis file Resolor MAA for chronic constipation

Movetis have filed a Marketing Authorization Application (MAA) submission for Resolor (prucalopride) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief.

Theravance describe synthesis of 5-HT1D ligands by dimerization of 5-HT1 ligands

Theravance describe a series of 5-HT1D ligands derived by dimerization of 5-HT1 ligands including LY-334370, a selective agonist of 5-HT1F receptor

Wyeth publish data on Relistor Phase III trials in Opioid induced Constipation

Results from a pivotal phase 3 trial of Relistor (methylnaltrexone bromide) subcutaneous injection have been publsihed in the in the May 29, 2008 issue of the New England Journal of Medicine. Results show that patients receiving Relistor had significantly more bowel movements within four hours of receiving their first dose than patients receiving [...]

EpiCept re-file Ceplene in Europe

EpiCept have filed re-examination MAA documents in Europe for Ceplene, its histamine dihydrochloride compound that is intended for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML). The EU CHMP previously issued a negative opinion, requiring further mechanistic data

JapanBridge license Asian rights to ProStrakans Sancuso (granisetron transdermal)

JapanBridge have licensed rights to ProStrakan’s Sancuso (granisetron transdermal delivery system) in Japan, China and several other nations throughout South East Asia.

US and WO patent update for the week ending 05/23

US and WO kinase patents have been updated for this week at GPCRCentral.com